Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established curative therapy for a variety of hematological malignancies [1] . Genotypically HLA-identical sibling donors (ISD) -being available for about 30 % of the Caucasian patients [2] -are still regarded as the best donors for HSCT [3] . However, for the remaining 70 % of patients alternative donors, i.e. (partially) HLA-matched family donors other than HLA-identical siblings (MFD) and HLA-A,B,C,DRB1,DQB1 matched unrelated (MUD) donors are meanwhile routinely accepted [4 -7] .
Fact is that the clinical outcome after HSCT from MFD [4, 8, 9] as well as MUD [10 -13] has meanwhile clearly improved, probably due to progress made in the domains of HLAtyping techniques [14 -16] and supportive therapy [17, 18] .
However, it is presently unclear, whether HSCT from MFD or from MUD has a superior outcome since the above cited clinical studies do not directly compare these two allogeneic approaches. Thus, the question is still open how to proceed if the donor search among the patients` siblings -which is always run first -has only identified a MFD, but no ISD. Should any or at least a subgroup of MFD (which remains to be defined) be accepted immediately without further effort to identify a MUD? Or should an unrelated donor search, even if expensive and time consuming, be run for all these patients?
The present clinical study directly compares the classical clinical endpoints of transplant outcome from MFD and MUD with ISD transplants serving as controls and identifies two subgroups of MFD which should not be a ccepted routinely for HSCT.
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Patients, Donors, and Methods
Entry criteria. Enrolled were all patients transplanted at our institution during the period form January 1, 1994 to July 31, 2000 if fulfilling the following entry criteria: (1) patient age 16 years, (2) allo-transplantation for chronic myeloid (CML), acute myeloid (AML), or acute lymphatic (ALL) leukemia, (3) first transplant, i.e. no preceding allo-or autotransplant, (4) no graft manipulation (e.g., no T cell depletion), (5) myeloablative conditioning regimen used (containing 4 x 2.5 Gy fractionated total body irradiation and cyclophosphamide), (6) cyclosporine plus short course methotrexate protocol used for GvHD prophylaxis, and (7) transplantations performed under strict regimens for gut decontamination of anaerobic bacteria and reverse isolation (laminar air flow conditions). At the time of analysis all enrolled patients (n = 325) who survived had a follow up of 18 months.
Strategy of donor search and selection of graft source. The strategy of donor search was in accordance with the "First German Consensus on Immunogenetic Donor Search" [19] . Thus, for patients lacking an ISD, an MFD was accepted (without a further effort to identify a MUD) if matched with the patient in GvH direction for at least five out of the six HLA-A, B, DRB1 antigens (irrespective of the number of additional HLA-mismatches in HvG-direction). If more than one MFD was available we tried to avoid selection of a female donor for a male patient and of a CMV negative donor for a CMV positive recipient.
Since October 1994, we preferred peripheral blood over marrow as graft source in patients with an increased risk of graft failure and/or with a recent serious infectious disease as outlined previously [9] .
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Histocompatibility studies. HLA class I (A, B, C) typing of patients and donors relied on conventional serology (supplemented by 1D-IEF) until 1996 and on low resolution DNA-based typing (PCR-SSP) thereafter. For the purposes of the present study > 90 % of donors and recipients belonging to the MFD group were retyped for HLA-A, B, C by low resolution PCR-SSP. For identification and selection of HLA class II (DRB1, DQB1) matched donors, the MLC test was routinely used until 1994, supplemented by HLA-DR, DQ serology. After 1994, the DRB1, DQB1 antigens of all donors and recipients were identified according to the German consensus on immunogenetic donor search [19] .
Thus, for patients and donors belonging to the ISD and MFD group low resolution PCR-SSP (generic level, two digit code) was used, supplemented by a high resolution typing technique in case of ambiguous results (e.g., homozygosity). In the MFD setting German experts did not feel a need for routine high resolution HLA-DRB1, DQB1 typing, if low resolution typing has already disclosed a donor/recipient DRB1 and/or DQB1 mismatch (e.g. DRB1 010x vs. 040x) and the test results were supported by a pedigree plot segregation analysis. In contrast high resolution PCR-SSP (allelic level, four digit code) was routinely employed in the unrelated donor-recipient setting. Table   1 on the times to achieve the analytical endpoints of transplant outcome was evaluated by Cox proportional hazard regression with backward eli mination of parame ters with a pvalue above 0.2. For the analysis of interactions, the variables of main interest "MFD: yes/no" and "MUD: yes/no" were forced to remain in the Cox model. Interactions between the variables "MFD: yes/no" and "MUD: yes/no" and the identified risk factors in the final Cox model were evaluated by including interaction terms (e.g., "patient age * MFD" and "patient age * MUD") one at a time and testing whether the explained deviation of the model exceeded the 0.95-quantile of the chi-square-distribution with one degree of freedom.
For graft failure as an event, the scarcity of events did not allow a higher-dimensional analy sis without severe risk of biased estimation. Therefore, an exploratory analysis of the biologically plausible variables was performed in order to test whether the obtained results are within the range of results reported by previously studies.
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Results

Overall Survival (OS)
Univariate statistical analysis showed the stage of disease and the age of the patient to have a marked influence on OS after HSCT. The 5-year OS rate, for example, reached 67 % for patients with early disease, but declined to 29 % for patients with advanced disease. The corresponding data for OS were 65 % for patients aged 37 years) but dropped down to 47 % for patients older than 37 years. In contrast, univariate analysis could not demonstrate any impact on OS of all other initial characteristics listed in Table 1 , including the type of donor used. In order to illustrate the results of univariate analysis, the OS curves for the three study group transplants (ISD, MFD, and MUD) are shown in Figure 1 after stratification for the dominating variable "stage of disease".
Multivariate statistical analysis revealed the parameters "disease stage", "patient age", "time interval between diagnosis and transplantation" as well as "donor age" to be independent risk factors for OS (cf. Table 3 ). In contrast, the type of donor was excluded from the Cox model for OS, irrespective of whether tested as "MUD: yes/no" (p = 0.6) or as "MFD: yes/no" (p = 0.4). For comparison with the explanatory parameters, listed in Table 3 Thus, in contrast to advanced disease and advanced patient age, the type of donor (ISD, MFD or MUD) had no significant impact on OS after HSCT in our study .
Treatment-related/Non relapse-related mortality (TRM)
Univariate statistical analysis. TRM was found to be clearly influenced by disease stage and patient age. The 5-year TRM, for example, was 38 % for patients with early but 60 % for patients with advanced disease, and 25 % for patients aged 37 years as compared to 48 % for patients older than 37 years. In contrast, the other initial variables listed in Table 1 including the type of donor had no significant influence on TRM. To illustrate the latter finding, we calculated the TRM for ISD, MFD and MUD group patients after stratification for the dominating risk factor, i. e. disease stage. For patients with early disease we documented a 5-year TRM of 27 %, 29 % and once again 29 % in the ISD, MFD, and MUD group, respectively. The corresponding percentages for patients with advanced disease were 55 %, 58 %, and 65 %, respectively.
Multivariate statistical analysis. Cox model building suggested three of the initial transplant characteristics listed in Table 1 to be independent risk factors for TRM, namely "disease stage", "patient age" and "donor age" (cf. Table 3 cases, and all observed 5 cases of GF were within the BM subgroup. In the MFD group, BM was used in 38 and PB in 46 cases. Of the 8 cases with graft failure, seven were within the BM and only one in the PB subgroup. For MFD patients the observed difference in the graft failure rate between BM and PB was significant (two sided Fisher`s exact test: p = 0.02).
Thus, the use of an MFD or a MUD instead of an ISD is clearly associated with a higher risk of GF.
Acute Graft-versus-Host Disease (aGvHD)
Univariate statistical analysis disclosed the risk of grades II-IV aGvHD to be influenced by three parameters, namely the type of donor (as depicted in Figure 2 ), patient age ( 37 years: 37 %, > 37 years: 60 %), and donor age ( 38 years: 39 %, > 38 years: 57 %).
Multivariate statistical analysis confirmed the above results since it suggested (p < 0.2) the following initial variables as independent risk factors for grades II-IV aGvHD: type of donor "MFD", type of donor "MUD", "patient age", "donor age", and "disease stage" (cf. Table 3 Thus, the risk of aGvHD is clearly increased after HSCT from MFD as well as from MUD as compared to ISD and appears to be especially high in case of patients with advanced age transplanted from MFD.
Relapse (REL)
Univariate statistical analysis identified several variables to influence the risk of REL. Multivariate statistical analysis confirmed the results given above since it suggested (with p < 0.2) the following independent risk factors for relapse: "disease stage", type of donor "MUD", type of donor "MFD", "graft source", and "sex mismatch" (cf. Table 3 ).
Thus, the use of a MFD or a MUD instead of an ISD seems to be protective (hazard ratio < 1) against relapse at least in patients with early disease.
Impact of HLA-mismatches
The data presented above demonstrated MFD and MUD group patients to be at a higher risk of aGvHD and of graft failure as compared to ISD group patients. However, the MFD group was very heterogeneous with regard to the pattern of donor/recipient HLA mismatches, as detailed in Table 1 . Thus, we decided to evaluate whether the documented increased risk of aGvHD and of GF of the MFD group can be attributed to transplants with special patterns of donor/recipient HLA -mismatches.
Impact of HLA-mismatches on aGvHD
The Kaplan-Meier procedure was used to calculate the risk of aGvHD for the following subgroups of transplants: "MFD class I" = MFD transplants with one or more HLA class I mismatches but no HLA class II mismatch in GvH-direction (n = 41), "MFD class II" = MFD transplants with no class I but one or two class II mismatches in GvH direction (n =21), "MFD no MM" = MFD transplants with no class I and no class II mismatch in GvHdirection (n =16), and MUD transplants. Outcome data of ISD transplants served as Most differences in initial characteristics between the three study cohorts documented in Table 1 were an integral part of the evaluated procedures, e.g., the higher mean donor age in the MFD group (since the patients` parents served as MFD in multiple cases) or the lower frequency of sex mismatched transplants in the MUD group (since exclusion of sex mismatched donors was only feasible when several donors were available for one patient, which is a rare event in the ISD and MFD settings). Nevertheless, all differences in initial characteristics were regarded as possibly confounding variables. Thus, results suggesting an impact of the parameter "type of donor used" on clinical outcome were only accepted if confirmed by multivariate analysis.
The sample size of the presented single center study appears to be sufficient with regard to the study objective, especially because the scientific question has not been adequately considered by other studies. However, even if the quality of the presented data allows for making valid statistical predictions, we are aware that the number of cases enrolled is comparatively low in view of the clinical impact of our main conclusions. This applies especially to our finding that overall survival appears to be similar between the three study groups (cf. Figure 1 and Table 3 ).
For
Our finding of a similar long-term overall survival between the three study groups is surprising at least at first glance since at the same time the present study demonstrated an increased risk of primary GF (cf. results, section 3) as well as acute GvHD grades II-IV (cf. results, section 4) in the MFD and MUD as compared to the ISD group, and GF as well as clinically relevant aGvHD are well known live threatening complications after HSCT.
However, our findings are in accordance with those of a recent large multicenter study, comparing the outcome after ISD and MUD transplants for CML [21] and may be explained as follows. In a statistical analysis focussing on long-term OS after HSCT the impact of GF on OS may become "invisible" for the following reasons: (1) Primary GF is a rare event even in the MFD (8.5 %) and MUD (5.2 %) groups and occurs early after transplant. Thus, more frequent causes of death may "dilute" the impact of GF on OS at the long term, and (2) patients being successfully re-transplanted after GF are notably not censured in the Kaplan-Meier analysis for OS. Furthermore, the adverse effect of acute GvHD on OS after transplantation from MFD or MUD seem to be compensated at the long-term by the documented reduced risk of relapse at least in patients transplanted for early disease (cf. Figure 3) . Anyhow, our finding of a similar OS after transplantation from ISD, MFD and MUD allows for two conclusions, (1) MFD and MUD donors, as defined by this study, are both acceptable in principal, if an ISD is not available and (2) the world-wide efforts in building up "unrelated marrow donor registries" were worthwhile [6, [22] [23] [24] .
Another important result of this study is that two subgroups of MFD transplants had an inferior outcome as compared to the ISD and MUD groups: (1) Donor/recipient HLA-class II (DRB1±DQB1) antigen mismatches in GvH-direction were associated with an increased risk of clinically relevant aGvHD (cf. Figure 4) and (2) Additionally, our study gave a detailed insight into the biology of HLA in the context of allogeneic HSCT from related donors. Obviously, HLA class II mismatches in GvHdirection play a key role for the development of aGvHD, whereas HLA class I mismatches in HvG direction have a major impact on the risk of graft failure. Of note, our findings on HLA biology in the related setting are identical to those of a recent study from Seattle analysing a large cohort of unrelated transplants [25] . Another point of interest is the relatively high relapse rate for the early disease group (cf. Figure 3) . A straightforward explanation for this phenomenon is that the use of an MFD or a MUD is only protective against relapse in case of early disease, but not in case of (generally more aggressive) advanced disease stages.
Finally, the data of this study indirectly contribute to the recent discussion of whether donor/recipient HLA-A,B,C sequence based typing (SBT) [26 -28] will improve the outcome after unrelated HSCT without compromising donor availability [29, 30] . Our present data clearly argue against the routine use of SBT. We did not employ this time-consuming typing technique and could nevertheless achieve the same long term OS results
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